The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Mylan Institutional Inc. (MIi) is conducting a recall at the retail level of the below listed batches of Levothyroxine Sodium Tablets, USP, manufactured for Mylan Pharmaceuticals Inc. (MPI) and repackaged by MIi in unit dose UDl00.

These batches are being recalled out of an abundance of caution due to corresponding parent lots assay results that are either atypical or out of specification.

The batches were distributed in the US between November 30, 2023 and November 6, 2024.

The potential risk to patients arising from this issue is considered to be negligible and to date, no reports of adverse reactions associated with these lots have been received.

Levothyroxine Sodium Tablets USP, is indicated in adult and pediatric patients, including neonates, for hypothyroidism and pituitary thyrotropin (thyroid-stimulating hormone, TSH) suppression.

PRODUCT	**Product, Strength & Form**	**NDC#**	**Size**	**MII Batch#**	**MII Exp. Date**
	Levothyroxine Sodium Tablets, USP 100 mcg	51079-442-20	UDI00	3115936	7/2025
	Levothyroxine Sodium Tablets, USP 112 mcg	42292-039-20	UDI00	3115707	2/2025
	Levothyroxine Sodium Tablets, USP 125 mcg	51079-443-20	UDI00	3115893	6/2025
	Levothyroxine Sodium Tablets, USP 137 mcg	42292-041-20	UDI00	3115448	12/2024
	Levothyroxine Sodium Tablets, USP 137 mcg	42292-041-20	UDI00	3115732	3/2025
	Levothyroxine Sodium Tablets, USP 137 mcg	42292-041-20	UDI00	3116024	9/2025
	Levothyroxine Sodium Tablets, USP 150 mcg	51079-445-20	UDI00	3115924	6/2025
	Levothyroxine Sodium Tablets, USP 175 mcg	42292-040-20	UDI00	3115869	3/2025